Antares Therapeutics

Boston, MA · Founded 2025 · Privately Held (backing)

Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets. Antares Therapeutics is based in Boston, MA and was founded in 2025. It is valued at about $299 million as of Oct 2026, set by institutional fund marks. It has raised $177 million across 2 recorded rounds; the latest was a $30 million early-stage round in May 2025.

PMV mark · valuation
$299.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$177.0M
Last round
Early Stage VC
May 2025

Who backs Antares Therapeutics?

11 investors
InvestorType
Lightspeed Venture PartnersVenture capital
Cormorant Asset ManagementVenture capital
Invus OpportunitiesVenture capital
Omega FundsPE / buyout
Atlas VentureOther
Willett AdvisorsFamily office
Abingworth—
BVF Partners—
Tenmile—
Vida Ventures (Los Angeles)—
+ 1 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Antares Therapeutics investors

11 investors are on record for Antares Therapeutics, including Lightspeed Venture Partners, Cormorant Asset Management, Invus Opportunities and Omega Funds. By type, the record holds 3 venture capital firms, 1 family office and 1 private equity firm. The early-stage round in May 2025 drew 35 investors.

Free account
More of Antares Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Antares Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 11 firms already write checks for companies like Antares Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View